Impact of E-cigarettes on Smoking and Related Outcomes in Veteran Smokers With Psychiatric Comorbidity

ABSTRACT

Objective: Compared to the general U.S. population, smokers with comorbid psychiatric and/or substance use disorders have lower quit rates after evidence-based treatments and disproportionately high smoking-related deaths. Improved modalities for reducing tobacco-related harm in this subpopulation are needed. Because electronic cigarettes (e-cigarettes) can now deliver physiologically relevant levels of nicotine to consumers, they represent an additional nicotine delivery system that could be used in cessation interventions. While current data suggest that the use of e-cigarettes by smokers promotes a reduction in combustible cigarette use, smoking quit rates through use of e-cigarettes appears to be low. The goal of this study was to examine impact of e-cigarette use on combustible tobacco use as well as on the readiness to quit smoking and changes in nicotine dependence in a multimorbid population. Methods: We conducted a 4-week, open-label study in 43 military veteran smokers who had no immediate intention to stop smoking and were currently receiving psychiatric services from the Department of Veterans Affairs health care system. Participants were provided with a study e-cigarette they could use ad libitum along with other tobacco products and were encouraged to attend weekly laboratory visits and a one-month follow-up visit. Main outcome measures were number of cigarettes smoked per day (CPD), the frequency of e-cigarette use, the amount of money spent on combustible cigarettes (U.S. dollars/week), alveolar carbon monoxide (CO) levels, and urine cotinine levels. Results: Mean e-cigarette use was 5.7 days per week and only 9% of participants used the e-cigarette for fewer than 4 days per week. Significant reductions in breath CO (9.3 ppm to 7.3 ppm, p < .02) and CPD (from 16.6 to 5.7, p < .001) were observed across study weeks, and no serious adverse events were reported. Three participants (10% of completers) reported smoking cessation that was corroborated biochemically. At one-month follow-up, motivation to quit smoking remained significantly higher and the level of nicotine dependence was significantly lower than at baseline. Conclusions: E-cigarettes are acceptable to smokers with psychiatric comorbidities, as indicated by sustained and frequent e-cigarette use by 90% of participants, and may promote reduction and/or cessation of combustible cigarette use. E-cigarettes appear to be a viable harm reduction modality in smokers with psychiatric comorbidities.

KEYWORDS:

• Electronic cigarettes
• e-cigarettes
• cigarettes
• smoking
• tobacco harm reduction

Acknowledgments

We thank Stacy Minnix, Michael J. Stevens, Lance Barnes, Christopher Cryan, Jeremy Merrel, and Ellen Mitchell for their important contributions to this study, including recruitment, administrative support, clinical evaluation of participants and data collection/management. In addition, we thank Tony Pace, PhD, for his contribution of e-liquid manufacturing expertise during the design phase of this study.

Disclosures

Ralitza Gueorguivea, PhD, discloses consulting fees for Palo Alto Health Sciences and Mathematica Policy Research and a provisional patent submission by Yale University: Chekroud, A. M., Gueorguieva, R., & Krystal, K. H. “Treatment Selection for Major Depressive Disorder” (filing date June 3, 2016, USPTO docket number Y0087.70116US00). The authors report no other financial relationships with commercial interests.

Additional information

Funding

This research was supported by the New England Mental Illness Research, Education and Clinical Center and the U.S. Department of Veterans Affairs. Statistical analyses, biochemical assays, and analyses of e-cigarette solutions were supported by the Administrative and Laboratory cores of P50DA036151 (Yale TCORS) from the National Institutes of Health and the U.S. Food and Drug Administration Center for Tobacco Products. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or of the U.S. Food and Drug Administration.